Toggle light / dark theme

Self-organizing ‘pencil beam’ laser could help scientists design brain-targeted therapies

MIT researchers discovered a paradoxical phenomenon in optical physics that could enable a new bioimaging method that’s faster and higher-resolution than existing technology. They discovered that, under the right conditions, a chaotic mess of laser light can spontaneously self-organize into a highly focused “pencil beam.”

Using this self-organized pencil beam, the researchers captured 3D images of the human blood-brain barrier 25 times faster than the gold-standard method, while maintaining comparable resolution. By showing individual cells absorbing drugs in real-time, this technology could help scientists test whether new drugs for neurodegenerative diseases like Alzheimer’s or ALS reach their targets in the brain, with greater speed and resolution.

“The common belief in the field is that if you crank up the power in this type of laser, the light will inevitably become chaotic. But we proved that this is not the case. We followed the evidence, embraced the uncertainty, and found a way to let the light organize itself into a novel solution for bioimaging,” says Sixian You, assistant professor in the MIT Department of Electrical Engineering and Computer Science (EECS), a member of the Research Laboratory for Electronics, and senior author of a paper on this imaging technique.

Scientists discover how to freeze transplant organs without cracking them

Scientists are making a major leap toward freezing organs for future use without damaging them. A new study reveals that one of the biggest obstacles—cracking during ultra-cold preservation—can be reduced by carefully tuning the temperature at which tissues enter a glass-like state. This breakthrough builds on recent successes in cryopreserved organ transplants and could bring the long-imagined idea of “banking” organs for later use much closer to reality.

Bacterial defense system builds DNA in unexpected new way to stop viruses

Scientists at Stanford University have discovered that DRT3, a unique defense system found in bacteria, creates DNA to protect against viral infections. DRT3 is made up of two different enzymes called reverse transcriptases, Drt3a and Drt3b, and a piece of noncoding RNA (ncRNA). Together, this trio makes long, double-stranded DNA consisting of alternating repeats (GT/AC).

The Why Is a Discipline: Goodhart’s Law and AI

A reader asked me a question this week that I have been thinking about ever since.

She did not ask whether AI could malfunction. She did not ask whether bad actors could misuse it. She asked something sharper:

Can a system produce bad outcomes systematically, even when intent is good, and nothing is broken?

The answer is yes. And it is the most dangerous category of bad outcome, because nobody is at fault and nothing is broken.

We have all the evidence we need. Amazon ran into it. YouTube ran into it. Hospitals are running into it now. AI labs are about to run into it at a planetary scale. And almost nobody is talking about why.

A 1975 economic principle explains it cleanly. A reader’s question forced me to refine an argument I have been making for years.

New essay: [ https://www.singularityweblog.com/goodharts-law-ai/](https://www.singularityweblog.com/goodharts-law-ai/)

Detecting multiple cancers and other diseases from a single blood sample

UCLA scientists have developed a simple and cost-effective blood test that, in early studies, shows promise in detecting multiple cancers, various liver conditions and organ abnormalities simultaneously by analyzing DNA fragments circulating in the bloodstream. The test, described in the journal Proceedings of the National Academy of Sciences, could offer a powerful and more affordable approach to early disease detection and comprehensive health monitoring.

“Early detection is crucial,” said Dr. Jasmine Zhou, the study’s senior author, a professor of pathology and laboratory medicine and investigator at the UCLA Health Jonsson Comprehensive Cancer Center. “Survival rates are far higher when cancers are caught before they spread. If you detect cancer at stage one, outcomes are dramatically better than at stage four.”

How the MethylScan blood test works The new method, called MethylScan, works by analyzing cell-free DNA (cfDNA), tiny fragments of genetic material released into the blood when cells die. Because cells from every organ shed DNA into the bloodstream, cfDNA carries molecular signals that reflect what is happening throughout the body.

Attenuation of malignant phenotype of glioblastoma following a short course of the pro-oxidant combination of Resveratrol and Copper

Background We investigated a novel therapeutic approach to glioblastoma (GBM) that targets cell-free chromatin particles (cfChPs) that are released from dying GBM cells and aggravate the oncogenic phenotype of living GBM cells. cfChPs can be deactivated by oxygen radicals (OR) generated upon oral administration of the nutraceuticals Resveratrol ® and Copper (Cu).

Methods Ten patients with glioblastoma awaiting surgery were administered 5.6 mg of Resveratrol ® and 560 ng of Copper (Cu) four times a day for an average of 11.6 ± 5.37 days. Another ten patients who did not receive R-Cu acted as controls. A tissue sample was taken at operation for analysis.

Results R-Cu treatment led to marked deactivation of cfChPs that were present in the tumour microenvironment, which was accompanied by a highly significant down-regulation in Ki-67, nine hallmarks of cancer, six immune check-points and three stem cell biomarkers as revealed by immuno-fluorescence analysis. Transcriptome sequencing detected marked upregulation of pro-apoptotic and down-regulation of anti-apoptotic genes. Also detected was down-regulation of PVRIG-2P, a homologue of immune checkpoint receptor PVRIG, which is a functional analogue of PD-L1.

CNS infiltration by zamtocabtagene autoleucel tandem CD20/CD19 CAR T cells leading to complete remission in a patient with primary CNS lymphoma

CAR T cells in primary CNS lymphoma.

Treatment options for primary central nervous system (CNS) lymphoma remain limited, particularly in relapsed or refractory disease. This case report explores the activity and CNS trafficking of tandem CD20/CD19 CAR T cells (zamtocabtagene autoleucel), addressing key questions about cellular therapy in CNS lymphoma and the potential role of dual-target CAR T strategies.


CD19-directed chimeric antigen receptor (CAR) T-cell (CAR T) therapy is a well-established treatment for B-cell malignancies, but accessibility, toxicities, lack of persistence, modest anti-tumor activity, restricted trafficking and tumor antigen escape are among its limitations.1 Concern for excessive neurotoxicity led to exclusion of patients with central nervous system (CNS) involvement from clinical trials, and primary CNS lymphoma (PCNSL) is an exclusion on the approved products’ labeling. PCNSL is a highly aggressive lymphoma, with a favorable response to initial chemotherapy/radiation, but compared with lymphomas outside the CNS, relapses are common, and survival is inferior. Moreover, there is a lack of approved standard care beyond first-line therapy and the prognosis for these PCNSL patients remains poor.2

In approximately one third of all B-cell lymphoma patients, resistance to CAR T and relapses are accompanied by CD19 downregulation. Preclinical evidence suggests that dual antigen-targeting may overcome this problem.3 To address antigen escape, the investigational anti-CD20/ anti-CD19 CAR T product MB-CART2019.1 (zamtocabtagene autoleucel [zamto-cel]) was designed. Zamto-cel is a dual-targeting tandem-CAR construct with scFv regions of anti-CD19 and anti-CD20 linked in sequence by a flexible interchain linker, followed by CD8, 4-1BB and CD3 ζ domains.4 Our group and others have evaluated zamto-cel in a pivotal phase II clinical trial (DALY II USA/ MB-CART2019.1; clinicaltrials gov. Identifier: NCT04792489) for the treatment of DLBCL patients who received at least two lines of treatment.5 In addition to addressing antigen escape/relapse zamto-cel is non-cryopreserved with a vein-to-vein time of 14 days, improving cell yield and potency.

/* */